Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry

Clinical Chemistry

Volumn 51, Issue 12, 2005, Pages 2229-2235

  Li, Jinong ^a   Orlandi, Rosaria ^b   White, C Nicole ^a   Rosenzweig, Jason ^a   Zhao, Jing ^a   Seregni, Ettore ^b   Morelli, Daniele ^b   Yu, Yinhua ^c   Meng, Xiao Ying ^d   Zhang, Zhen ^a   Davidson, Nancy E ^a   Fung, Eric T ^d   Chan, Daniel W ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d CIPHERGEN BIOSYSTEMS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; TUMOR MARKER;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; BENIGN TUMOR; BREAST CANCER; BREAST DISEASE; CANCER DIAGNOSIS; CARCINOMA IN SITU; CASE CONTROL STUDY; CHROMATOGRAPHY; CONTROLLED STUDY; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; GEL ELECTROPHORESIS; HUMAN; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOASSAY; MIDDLE AGED; NEOPLASM PROTEINS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 28044471999     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.052878     Document Type: Article

References (30)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Antman K, Shea S. Screening mammography under age 50. JAMA 1999;281:1470-2.
3. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2004. CA Cancer J Clin 2004;54:41-52.
4. Chan DW, Sell S. Tumor markers. In: Burtis CA, Ashwood ER, eds. Tietz textbook of clinical chemistry, 3rd ed. Philadelphia: WB Saunders, 1999:390-413.
5. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-304.
6. Jorgensen CS, Jagd M, Sorensen BK, McGuire J, Barkholt V, Hojrup P, et al. Efficacy and compatibility with mass spectrometry of methods for elution of proteins from sodium dodecyl sulfate-polyacrylamide gels and polyvinyldifluoride membranes. Anal Biochem 2004;330:87-97.
7. Janeway CA Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 1992; 13:11-6.
8. Sahu A, Sunyer JO, Moore WT, Sarrias MR, Soulika AM, et al. Structure, functions, and evolution of the third complement component and viral molecular mimicry. Immunol Res 1998;17:109-21.
9. Sahu A, Lambris JD. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity, Immunol Rev 2001;180:35-48.
10. Bohana-Kashtan O, Ziporen L, Donin N, Kraus S, Fishelson Z. Cell signals transduced by complement. Mol Immunol 2004;41:583-97.
11. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004;41:355-67.
12. Sim RB, Tsiftsoglou SA. Proteases of the complement system. Biochem Soc Trans 2004;32:21-7.
13. Fischer WH, Hugli TE. Regulation of B cell functions by C3a and C3a(desArg): suppression of TNF-α, IL-6, and the polyclonal immune response. J Immunol 1997;159:4279-86.
14. Carli M, Bucolo C, Pannunzio MT, Ongaro G, Businaro R, Revoltella R. Fluctuation of serum complement levels in children with neuroblastoma. Cancer 1979;43:2399-404.
15. Nishioka K, Kawamura K, Hirayama T, Kawashima T, Shimada K. The complement system in tumor immunity: significance of elevated levels of complement in tumor bearing hosts. Ann N Y Acad Sci 1976;276:303-15.
16. Gminski J, Mykala-Ciesla J, Machalski M, Drozdz M, Najda J. Immunoglobulins and complement components levels in patients with lung cancer. Rom J Intern Med 1992;30:39-44.
17. Maness PF, Orengo A. Serum complement levels in patients with digestive tract carcinomas and other neoplastic diseases. Oncology 1977;34:87-9.
18. Matsutani M, Suzuki T, Hori T, Terao H, Takakura K, Nishioka K. Cellular immunity and complement levels in hosts with brain tumours. Neurosurg Rev 1984;7:29-35.
19. Mangano A, Messina L, Birgillito S, Stivala F, Bernardini A. Complement and its fractions (C3-C4) pattern in subjects with neoplasia. J Immunopharmacol 1984;6:147-62.
20. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-14.
21. Adam PJ, Boyd R, Tyson KL, Fletcher GC, Stamps A, Hudson L, et al. Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J Biol Chem 2003;278:6482-9.
22. Clarke W, Silverman BC, Zhang Z, Chan DW, Klein AS, Molmenti EP. Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg 2003;237:660-4; discussion 664-5.
23. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10:860-8.
24. Paweletz CP, Track B, Pennanen M, Tsangaris T, Magnant C, Liotta LA, et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001;17:301-7.
25. Petricoin I, Emanuel F, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
26. Rosty C, Christa L, Kuzdzal S, Baldwin WM, Zahurak ML, Carnot F, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002; 62:1868-75.
27. Vlahou A, Laronga C, Wilson L, Gregory B, Fournier K, McGaughey D, et al. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 2003;4:203-9.
28. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001;158:1491-502.
29. Vlahou A, Schorge JO, Gregory BW, Coleman RL. Diagnosis of ovarian cancer using decision tree classification of mass spectral data. J Biomed Biotechnol 2003;2003:308-14.
30. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004;96:353-6.